Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

• Hauptverfasser: Sarah Cadot (Verfasst von), Carine Valle (Verfasst von), Marie Tosolini (Verfasst von), Frederic Pont (Verfasst von), Laetitia Largeaud (Verfasst von), Camille Laurent (Verfasst von), Jean Jacques Fournie (Verfasst von), Loic Ysebaert (Verfasst von), Anne Quillet-Mary (Verfasst von)
• Format: Buch
• Veröffentlicht: BMC, 2020-12-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Background Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CLL evolution under ibrutinib therapy are well chara...